Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen “Dear Doctor” Letter Warns Of Risk Of Death Associated With Aranesp

This article was originally published in The Pink Sheet Daily

Executive Summary

Letter follows release of data in patients receiving darbepoetin alfa who have anemia that is not due to concurrent chemotherapy, an off-label use.

You may also be interested in...



Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients

Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.

Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients

Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.

Aranesp, Epogen Share In CKD, ESRD Will Remain Stable Despite Hemoglobin Targets – JP Morgan

After surveying nephrologists, JP Morgan analysts predict that use of the erythropoiesis-stimulating agents in kidney disease settings will not change dramatically.

Related Content

Topics

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel